178 related articles for article (PubMed ID: 14975808)
1. [Colon cancer: what is new in 2004?].
André T; Louvet C; de Gramont A
Bull Cancer; 2004 Jan; 91(1):75-80. PubMed ID: 14975808
[TBL] [Abstract][Full Text] [Related]
2. Clinical overview: adjuvant therapy of gastrointestinal cancer.
Macdonald JS
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S4-11. PubMed ID: 15309508
[TBL] [Abstract][Full Text] [Related]
3. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy of stage III colon cancer.
Benson AB
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S74-7. PubMed ID: 16399437
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future.
Sabharwal A; Kerr D
Expert Rev Anticancer Ther; 2007 Apr; 7(4):477-87. PubMed ID: 17428169
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of colon cancer: current status and future directions.
Chung KY; Saltz LB
Cancer J; 2007; 13(3):192-7. PubMed ID: 17620769
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
10. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
Benson AB
Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
[TBL] [Abstract][Full Text] [Related]
11. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
12. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO
Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437
[TBL] [Abstract][Full Text] [Related]
14. Targeted agents for adjuvant therapy of colon cancer.
de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S42-5. PubMed ID: 17178286
[TBL] [Abstract][Full Text] [Related]
15. [Recent progress in the treatment of colorectal cancer].
Thuss-Patience PC; Reichardt P; Riess H; Kretzschmar A
Med Klin (Munich); 2006 Feb; 101(2):114-9. PubMed ID: 16501908
[TBL] [Abstract][Full Text] [Related]
16. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
18. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
19. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
20. New systemic frontline treatment for metastatic colorectal carcinoma.
Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
